Guardant Health, Inc. (GH) Stock
GH Key Statistics
About Guardant Health, Inc.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
CEO: Helmy Eltoukhy. Company website
GH — Frequently Asked Questions
What is the GH stock price today?
Guardant Health, Inc. (GH) trades at $179.38, down 2.03% on the day, as of Sep 20, 2026 14:59 UTC.
What is Guardant Health, Inc.'s market cap?
Guardant Health, Inc. has a market capitalisation of $24.07B, calculated from the live GH share price and shares outstanding.
What is the P/E ratio of GH?
GH has no meaningful price-to-earnings ratio: Guardant Health, Inc. lost $3.49 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Guardant Health, Inc. make?
Guardant Health, Inc. generated revenue of $1.18B over the trailing twelve months, which puts the stock at 20.35 times sales.
What is the 52-week range for GH?
GH has traded between $53.40 and $183.51 over the past 52 weeks, and the last price is 2.3% below that high.
Is Guardant Health, Inc. profitable?
No. Guardant Health, Inc. is loss-making, with a net margin of -38.33% over the trailing twelve months.
What is the analyst price target for GH?
Wall Street analysts rate GH Buy, with an average price target of $199.40, 11.2% above the current price.
What sector is Guardant Health, Inc. in?
Guardant Health, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Guardant Health, Inc.?
Helmy Eltoukhy is the chief executive of Guardant Health, Inc., which employs 2,498 people.
Where can I track GH in real time?
QFI Terminal shows GH with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See GH live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open GH in Terminal See plans